Cingulate Inc. (CIN) Prices 4.17M Share IPO at $6/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Kroger (KR) To Cut Corporate Workforce By About 3,000 Over 3 Years - Bloomberg
Cingulate Inc. Announces Pricing of $25.0 Million Initial Public Offering
December 7, 2021 9:05 PM ESTKANSAS CITY, Kan., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Cingulate Inc. (Cingulate or the Company), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation products, today announced the pricing of its initial public offering of 4,166,666 shares of common stock and accompanying warrants to purchase 4,166,666 shares of common stock.
Each share of common stock is being sold together with one warrant to purchase one share of common stock with an exercise price of $6.00 at a combined public offering price of $6.00 per share and accompanying warrant. All of the... More



